10:19 AM EDT, 08/17/2026 (MT Newswires) -- Nestlé (NESN.SW) sees the growing use of GLP-1 weight-loss drugs as a "huge opportunity" for the company, Reuters reported Monday, citing its chief technology officer. Stefan Palzer said the Swiss food giant is using artificial intelligence and other technologies to analyze clinical research, identify nutrient combinations, and develop products for consumers taking medicines like Ozempic and Wegovy.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.